Jenburkt Pharmaceuticals Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Standalone Quarterly Results

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Mar 2026 is 3.74% vs -5.58% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 82.97% vs -41.63% in Dec 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is 92.05% vs -43.36% in Dec 2025

Interest

QoQ Growth in quarter ended Mar 2026 is 8.33% vs 9.09% in Dec 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

Compare Quarterly Results Of Jenburkt Pharma With

Select Peers

Figures in Cr

Standalone Quarterly Results

Change(INR)

Change(%)

Net Sales

44.63

80.72

-36.09

-44.71%

Other Operating Income

0.00

Total Operating income

44.63

80.72

-36.09

-44.71%

Raw Material Cost

2.19

39.36

-37.17

-94.44%

Purchase of Finished goods

8.70

0.00

8.70

(Increase) / Decrease In Stocks

-2.23

-0.21

-2.02

-961.90%

Employee Cost

9.52

12.46

-2.94

-23.60%

Power Cost

0.00

Manufacturing Expenses

0.00

14.95

-14.95

-100.00%

Selling and Distribution Expenses

0.00

Other Expenses

12.20

2.60

9.60

369.23%

Total Expenditure (Excl Depreciation)

30.38

69.16

-38.78

-56.07%

Operating Profit (PBDIT) excl Other Income

14.25

11.56

2.69

23.27%

Other Income

4.35

0.08

4.27

5,337.50%

Operating Profit (PBDIT)

18.60

11.64

6.96

59.79%

Interest

0.13

1.46

-1.33

-91.10%

Exceptional Items

-3.95

0.00

-3.95

Gross Profit (PBDT)

14.52

10.18

4.34

42.63%

Depreciation

0.81

2.69

-1.88

-69.89%

Profit Before Tax

13.71

7.49

6.22

83.04%

Tax

2.86

2.08

0.78

37.50%

Provisions and contingencies

0.00

Profit After Tax

10.85

5.41

5.44

100.55%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

10.85

5.41

5.44

100.55%

Equity Capital

4.41

3.02

1.39

46.03%

Face Value

10.00

0.00

Reserves

0.00

Earnings per share (EPS)

24.60

17.91

6.69

37.35%

Diluted Earnings per share

24.58

17.88

6.70

37.47%

Operating Profit Margin (Excl OI)

31.93%

14.32%

0.00

17.61%

Gross Profit Margin

32.53%

12.61%

0.00

19.92%

PAT Margin

24.31%

6.70%

0.00

17.61%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 44.63 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 3.74% vs -5.58% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 8.72% vs 5.69% in Mar 2025

Quarterly - Standalone Net Profit

Standalone Net Profit 10.85 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 82.97% vs -41.63% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 27.05% vs 8.38% in Mar 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 14.25 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 92.05% vs -43.36% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 31.22% vs 10.25% in Mar 2025

Quarterly - Interest

Interest 0.13 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 8.33% vs 9.09% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 18.18% vs 83.33% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 31.93%

in Mar 2026

Figures in %

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025